Informations générales (source: ClinicalTrials.gov)
REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (REPERFUSE)
Interventional
Phase 3
Fondation Ophtalmologique Adolphe de Rothschild (Voir sur ClinicalTrials)
mars 2022
janvier 2027
02 février 2026
The main objective is to evaluate the efficacy of IV administration of the P2Y12
inhibitor (cangrelor) in addition to mecanich thrombectomy and WMD versus mecanich
thrombectomy and WMD alone on the functional prognosis at 3 months, in patients with
acute ischemic stroke eligible for mecanich thrombectomy on the basis of infusion imaging
between 0 and 24 hours after the onset of symptoms.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL FOCH | BERTRAND LAPERGUE | 04/05/2026 07:26:02 | Contacter | ||
| HOPITAL FOCH | BERTRAND LAPERGUE | 26/01/2026 08:41:31 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| HOPITAL FONDATION A. DE ROTHSCHILD | Mikael MAZIGHI, Pr | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hôpital Central (CHU de Nancy) - 54000 - Nancy 2990999 - France | Benjamin GORY, Pr | Contact (sur clinicalTrials) | |||
| Hôpital Purpan (CHU de Toulouse) - 31300 - Toulouse 2972315 - France | Jean-François ALBUCHER, MD | Contact (sur clinicalTrials) | |||
| Hôpital Salengro (CHU Lille) - 59037 - Lille 2998324 - France | Lucie DELLA SCHIAVA, MD | Contact (sur clinicalTrials) | |||
| Hospices civils de Lyon, Hôpital Pierre Wertheimer - 69500 - Bron 3029931 - France | Tae-Hee CHO, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHU de Besançon - 25030 - Besançon 3033123 - France | Guillaume, MD, PhD | Contact (sur clinicalTrials) | |||
| CHU de Strasbourg - 67200 - Strasbourg 2973783 - France | Raoul POP | Contact (sur clinicalTrials) | |||
| CHU La Timone - 13005 - Marseille 2995469 - France | Laurent SUISSA, MD-PhD | Contact (sur clinicalTrials) | |||
| Hôpital Dupuytren (CHU Limoges) - 87000 - Limoges 2998286 - France | Aymeric ROUCHAUD, Pr | Contact (sur clinicalTrials) | |||
| Hôpital Lariboisière AP-HP - 75010 - Paris 2988507 - France | Alexis, GUEDON | Contact (sur clinicalTrials) | |||
| Hôpital Pellegrin (CHU de Bordeaux) - Bordeaux 3031582 - France | Gaultier MARNAT, MD | Contact (sur clinicalTrials) | |||
| Hôpital Pitié-Salpêtrière AP-HP - 75013 - Paris 2988507 - France | Charlotte Rosso, Pr | Contact (sur clinicalTrials) | |||
Critères
Tous
- Age 18 or older
- Anterior circulation intracanial large artery occlusion isolated (Intracranial ICA
and/or MCA) proved on CTA or MRA.
- Symptoms onset < 24h at imaging
- Indication for MT and fulfillment of the following brain imaging criteria :
1. Perfusion imaging: An initial infarct volume (ischemic core on DWI or CTP
calculated by the RAPID software) of less than 70 ml, a ratio between the
critically hypoperfused lesion volume (calculated by RAPID with a TMax>6s) and
initial infarct volume of 1.8 or more, and an absolute difference between those
2 volumes of 15 ml or more.
OR (if perfusion imaging not available or uninterpretable) :
2. CORE CLINICAL MISMATCH: Core calculated on DWI by RAPID, <25 mL if NIHSS 6-20
and <50 mL if NIHSS>20
OR (if RAPID results are not considered reliable by the clinician) :
3. CORE CLINICAL MISMATCH according to the clinician evaluation
- Pre-stroke mRS ≤ 2
- NIHSS ≥ 6
Exclusion Criteria:
- Contraindication to MT
- Patient over 80 years old with >10 microbleeds on pre-treatment MRI
- Pre-existing dependency with mRS ≥3.
- Known tandem ICA-MCA occlusions requiring stenting
- ASPECT<6 on NCCT or DWI-MRI
- Known hypersensitivity to cangrelor or to any of the excipients (mannitol, sorbitol)
- History of previous intracranial hemorrhage
- Evidence of active bleeding or acute trauma (fracture) on examination
- Recent surgery with a significant risk of bleeding
- VKA oral anticoagulation with INR >1.7
- Curative heparin or direct oral anticoagulants (DOACs) in previous 48 hours with
specific DOAC dosage ≥50 ng/ml and abnormal thrombin time for patients on dabigatran
or abnormal specific anti-Xa activity for patients on apixaban, edoxaban, or
rivaroxaban
- Platelet count <100 000/ mm3
- Woman of childbearing age without a pregnancy test or with a positive serum
pregnancy test
- Patient benefiting from a legal protection
- Non-membership of a national insurance scheme
- Opposition of the patient or (in case of inclusion as a matter of urgency) of the
trustworthy person
- Participation in another study regarding AIS care interfering with this study.